Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy-Reference-Cited by-同舟云学术

Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy

Published:2019-06-25 Issue:9 Volume:98 Page:2121-2129
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Umino Kento,Fujiwara Shin-ichiro,Ikeda Takashi,Kawaguchi Shin-ichiro,Toda Yumiko,Ito Shoko,Ochi Shin-ichi,Nagayama Takashi,Mashima Kiyomi,Minakata Daisuke,Nakano Hirofumi,Yamasaki Ryoko,Morita Kaoru,Kawasaki Yasufumi,Yamamoto Chihiro,Ashizawa Masahiro,Hatano Kaoru,Sato Kazuya,Oh Iekuni,Ohmine Ken,Muroi Kazuo,Kanda Yoshinobu

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-019-03738-3.pdf

Reference27 articles.

1. Ansell SM (2018) Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol 93(5):704–715. https://doi.org/10.1002/ajh.25071

2. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569

3. Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, Ho A, Dorken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Dohner H, Borchmann P, Muller-Hermelink HK, Muller RP, Engert A (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol Off J Am Soc Clin Oncol 28(27):4199–4206. https://doi.org/10.1200/jco.2010.29.8018

4. Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Boll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A (2015) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 385(9976):1418–1427. https://doi.org/10.1016/s0140-6736(14)61469-0

5. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327(21):1478–1484. https://doi.org/10.1056/nejm199211193272102

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective study;BMC Cancer;2022-04-14

2. Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: a multi-center retrospective cohort study;Modern Rheumatology;2021-02-15

3. Risk, Diagnostic and Predictor Factors for Classical Hodgkin Lymphoma in HIV-1-Infected Individuals: Role of Plasma Exosome-Derived miR-20a and miR-21;Journal of Clinical Medicine;2020-03-11